2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-107326
    Bunazosin 80755-51-7 98.52%
    Bunazosin is a potent and selective α1-adrenoceptor antagonist. Bunazosin can be used for antihypertensive and ocular hypotensive research.
    Bunazosin
  • HY-107335
    Aplodan 6903-79-3 99.20%
    Aplodan (Creatinol O-phosphate) is an antiischemic and antiarrhythmic agent. Aplodan has a protective action on cell membrane. Aplodan has the potential for the research of ischemic heart or acute myocardial infarction .
    Aplodan
  • HY-107348
    Etofylline clofibrate 54504-70-0 99.77%
    Etofylline clofibrate has ypolipidemic and antithrombotic effect. Etofylline clofibrate has an agonistic interaction with intimal PGI2.
    Etofylline clofibrate
  • HY-107546
    CFM 1571 hydrochloride 1215548-30-3 ≥99.0%
    CFM 1571 hydrochloride is the stimulator of the nitric oxide receptor, soluble guanylate cyclase (sGC) with an EC50 and IC50 of 5.49 μM and 2.84 μM, respectively. Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO). CFM 1571 hydrochloride has the potential for the research of cardiovascular and other diseases.
    CFM 1571 hydrochloride
  • HY-107659
    YM-244769 hydrochloride 837424-39-2 99.02%
    YM-244769 hydrochloride is a potent, selective and orally active Na+/Ca2+ exchanger (NCX) inhibitor. YM-244769 hydrochloride preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 hydrochloride efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 hydrochloride can also increase urine volume and urinary excretion of electrolytes in mice.
    YM-244769 hydrochloride
  • HY-108322
    NBTGR 13153-27-0 ≥98.0%
    NBTGR (p-Nitrobenzylthioguanosine) is a potent inhibitor of nucleoside transport; inhibits adenosine uptake with a Ki of 70 nM.
    NBTGR
  • HY-108353
    Isoprenaline 7683-59-2 98%
    Isoprenaline is a non-selective, orally active β-adrenergic receptor agonist. Isoprenaline has potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities. Isoprenaline can be used for the research of bradycardia and bronchial asthma.
    Isoprenaline
  • HY-108482
    CP-96,345 132746-60-2 ≥99.0%
    CP-96,345 is a specific, highly potent, and orally active tachykinin and substance P receptor non-peptide inhibitor. CP-96,345 prevents the drop in blood pressure evoked by substance P and neurokinin A. CP-96,345 can be used for researching neurogenic inflammation.
    CP-96,345
  • HY-108565
    BMY 45778 152575-66-1 98.98%
    BMY 45778 is a non-prostanoid prostacyclin mimetic. BMY 45778 inhibits human (IC50 = 35 nM), rabbit (IC50: 136 nM) and rat (IC50 : 1.3 μM) platelet aggregation. BMY 45778 also activates adenylyl cyclase. BMY 45778 is a partial agonist at the prostacyclin receptor.
    BMY 45778
  • HY-108600
    CGP-53353 145915-60-2 98.87%
    CGP-53353 (DAPH-7) is an potent PKC inhibitor with IC50s of 0.41 μM and 3.8 μM for PKCβII and PKCβI, respectively. CGP-53353 can inhibit glucose-induced cell proliferation and DNA synthesis in AoSMC and A10 cells. CGP-53353 can be used for researching atherosclerosis of diabetic patients.
    CGP-53353
  • HY-109122
    Selatogrel 1159500-34-1 99.75%
    Selatogrel (ACT-246475) is a reversible and selective P2Y12 receptor antagonist which inhibits platelet aggregation with an IC50 of 8 nM. Selatogrel exhibits antithrombotic efficacy.
    Selatogrel
  • HY-109592
    Imidaprilate 89371-44-8
    Imidaprilate is an active metabolite of TA-6366, acts as a potent angiotensin converting enzyme (ACE) inhibitor, with an IC50 of 2.6 nM, and is used in the research of hypertensive disease.
    Imidaprilate
  • HY-109877
    Ro 22-3581 10041-06-2 99.91%
    Ro 22-3581 (4'-(Imidazol-1-yl) acetophenone) is a selective thromboxane (Tx) synthetase inhibitor.
    Ro 22-3581
  • HY-110116
    SD-2590 hydrochloride 226395-93-3 ≥99.0%
    SD-2590 hydrochloride is a potent MMP inhibitor with IC50 values of ﹤0.1, ﹤0.1, 0.18, and 1.7 nM for MMP2, MMP13, MMP9, and MMP8, respectively. SD-2590 hydrochloride inhibits dilation of the left ventricle in rats.
    SD-2590 hydrochloride
  • HY-111013
    VK-II-86 955371-84-3
    VK-II-86 is a Carvedilol (HY-B0006) analogue lacking antagonist activity at β-adrenoceptors, in hypokalaemia. VK-II-86 prevents hypokalaemia-induced ventricular arrhythmia through multi-channel effects. VK-II-86 prevents all hypokalaemia-induced changes in ion channel activity and oxidative stress.
    VK-II-86
  • HY-111014
    VK-II-36 955371-66-1 99.63%
    VK-II-36 is a carvedilol analog that suppresses sarcoplasmic reticulum Ca2+release but does not block the β-receptor.VK-II-36 inhibits triggered activities evoked by both early and delayed after depolarizations.
    VK-II-36
  • HY-111447
    VAS 3947 869853-70-3 99.59%
    VAS 3947, a specific NADPH oxidase (NOX) inhibitor, exerts a potent antiplatelet effect. VAS3947 induces apoptosis independently of anti-NOX activity, via UPR activation, mainly due to aggregation and misfolding of proteins.
    VAS 3947
  • HY-112070
    Oxyfedrine 15687-41-9 98%
    Oxyfedrine, a vasodilator, is an orally active β-adrenoreceptor agonist. Oxyfedrine decreases the tonicity of coronary vessels. Oxyfedrine can be used in the research of cardiovascular disease.
    Oxyfedrine
  • HY-112071
    Prenalterol 57526-81-5 99.18%
    Prenalterol is a selective β1-adrenergic receptor agonist. Prenalterol has no effect on gut smooth muscle contractile activity. Prenalterol can be used for researching cardiovascular disease.
    Prenalterol
  • HY-112143
    STOCK2S-26016 332922-63-1 98.7%
    STOCK2S-26016 is a WNK signalling inhibitors. STOCK2S-26016 inhibits WNK4 and WNK1 with IC50s of 16 μM and 34.4 μM, respectively. STOCK2S-26016 has potential for antihypertensive research.
    STOCK2S-26016
Cat. No. Product Name / Synonyms Application Reactivity